Currently Viewing:
American Society of Clinical Oncology Annual Meeting
Currently Reading
Persephone Trial: Cutting Trastuzumab Duration by Half Safer, Efficacious in HER2-Positive Breast Cancer
May 29, 2018
Despite USPSTF Recommendations, Lung Screening Rates Low Among Heavy Smokers
May 31, 2018
Nelarabine With Chemotherapy Boosted Outcomes in Pediatric and YA Patients With T-Cell Cancers
June 01, 2018
Dr Leonard B. Saltz on Deciding When a Patient Should Receive NGS Testing
June 02, 2018
Promising Early Phase Results With bb2121 CAR T Treatment in Relapsed Refractory Multiple Myeloma
June 02, 2018
Dr Peter Paul Yu Discusses the Impact of Health Information Technology in Oncology
June 02, 2018
Identifying Rational Immunotherapy Combinations for Glioblastoma: A Progress Report
June 02, 2018
Dr James Lin Chen Outlines Information Needs in Era of Precision Medicine
June 02, 2018
Ellen Miller Sonet Highlights Financial Burdens of Patients With Cancer
June 02, 2018
Utilization Management in Oncology: Current Strategies and a Path Forward
June 02, 2018
Immune Checkpoint Inhibitors Improve Outcomes in Mismatch Repair Deficient CRC, but Can Induce irAEs
June 02, 2018
ZUMA-1: Response to Axi-cel at Three Months Prognostic for Remission in B-cell Lymphoma
June 03, 2018
Cetuximab With Chemoradiation Worse Than Chemoradiation Alone in Older Patients With HNSCC
June 03, 2018
Dr Michael Thompson: The Role of Precision Medicine in the Community Setting
June 03, 2018
Dr Victoria Villaflor Outlines Challenges With Pursuing Precision Medicine
June 03, 2018
Clinical Trials: Sharing the Road With Real-World Evidence
June 04, 2018
Phase 3 TAILORx Results Confirm Chemotherapy Unnecessary in 70% of Women With Early-Stage Breast Cancer
June 04, 2018
KEYNOTE-042 Confirms First-Line Pembrolizumab Superior to Chemotherapy in PD-L1–Low Advanced NSCLC
June 04, 2018
Cemiplimab, in GOG 3016, Looks to Break New Ground for Immunotherapy in Cervical Cancer
June 04, 2018
Nearly Half of Patients With Metastatic CSCC Respond to Cemiplimab, on Fast Track at FDA
June 04, 2018
Opdivo Plus Chemo Boosts Progression-Free Survival 26% Over Chemo Alone in Late-Stage NSCLC
June 04, 2018
Managing Cancer-Related Pain in the Era of the Opioid Crisis
June 06, 2018
Discussing the Cost Burden of Cancer With Patients
June 06, 2018
Study Underscores Value of PROs in Improving Lung Cancer Survival
June 07, 2018

Dr Sara M. Tolaney: Standard of Care, Novel Approaches for Treatment of HER2-Positive Breast Cancer

There are a lot of new and exciting agents that are being explored for metastatic HER2-positive disease, explained Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute.


There are a lot of new and exciting agents that are being explored for metastatic HER2-positive disease, explained Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute.

Transcript

What’s the current standard of care for HER2-positive breast cancer?

In the metastatic setting, generally, we start out using a taxane with trastuzumab and pertuzumab, and then upon progression, we go on to trastuzumab DM1, and then thereafter, it’s really chemotherapy combined with anti-HER2 therapy. In patients who have hormone-receptor-positive HER2-positive disease, we sometimes will integrate endocrine therapy with dual anti-HER2 therapy along the course of their therapy.

What novel approaches are being taken for the treatment of HER2-positive breast cancer?

There are a lot of new and exciting agents that are being explored for metastatic HER2-positive disease. I think one particular class that’s exciting are the antibody-drug conjugates. So, there’s one agent, the DS-8201a agent. So, it’s an antibody-drug conjugate targeting HER2, and it delivers a topoisomerase 1 payload. They’ve demonstrated about a 60% objective response in metastatic HER2-positive breast cancer, and they uniquely even have activity in HER2-low-positive tumors, with about a 30% response.

Outside of that agent, which is made by Daiichi, there’s several other antibody-drug conjugates. So, here we saw results from a trial looking at SYD985, which is an antibody-drug conjugate that delivers a DNA alkylator payload, and they demonstrated a little over a 30% objective response in pretreated HER2-positive disease. Those 2 agents, along with several other antibody-drug conjugates that are coming along, including now even bispecific antibody-drug conjugates, I think, may really be a great opportunity for a lot of our patients, because you could imagine these agents may either be better than T-DM1 and replace it in the second line setting, or could work in T-DM refractory patients, and so really move into the third line setting.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up